FC Bundestag celebrates such values as cosmopolitanism and tolerance, and denounces “racism and xenophobic tendencies”. But hard-right politicians are claiming foul play https://t.co/P3AmjPan3i ...

New research published in the journal Frontiers in Psychology surveyed more than 1,000 people about their sleep and eating habits. It found that those who had worse symptoms of lactose intolerance also had more intense nightmares. You know, it's interesting.It was a thousand participants in this study and they looked at it and they correlated a couple things. One, how they slept, what happened when they slept as in their dreams and what they ate before they went to sleep. And like you mentioned, you know, 5 ...

New York City is celebrating Pride today. And while many of us are as excited as ever to lift up our LGBTQ community, this year's festivities feel bittersweet. Not only is the Trump administration once again doing nothing to recognize Pride Month, they and their allies, their MAGA allies, are actively working to roll back many of the advances the community has fought.so hard to achieve. During his first three months back in office, the administration has signed numerous executive orders curtailing legal pro ...

Risk tolerance is the degree of risk that an investor is willing to endure given the volatility in the value of an investment. https://t.co/NhWBi9WKin ...

Summary of Esperion Therapeutics Conference Call Company Overview - Esperion Therapeutics has been operational since 2008, gaining prominence with the launch of Nexlitol and Nexlazet in 2020 [5][6] - The company is focused on both commercializing drugs and developing a robust pipeline, including a new asset for primary sclerosing cholangitis (PSC) [6][7] Commercial Performance - Esperion is the only non-statin drug with primary prevention capabilities, which has resonated well with primary care physicians and cardiologists [9][10] - The company reported growth in a flat market, with positive trends continuing into the second quarter [10][12] - Adoption of Nexlitol and Nexlazet has increased, particularly among physicians who previously did not prescribe these drugs, attributed to the statin intolerance message [12][13] Market Dynamics - The total addressable market (TAM) for Nexlitol and Nexlazet increased from 10 million to 70 million patients post-clear outcome study [17] - Medicare plans have shown a 72% adoption rate, with some eliminating prior authorization requirements, facilitating easier access for patients [18][19] - The recent redesign of Medicare Part D has resulted in lower out-of-pocket costs for patients, enhancing drug accessibility [20][22] Sales Force Expansion - Esperion expanded its sales force by 72 individuals, totaling 155 sales representatives, and increased field reimbursement managers from 6 to 15 [25][26] - The expansion has already shown qualitative improvements in approval rates for drug prescriptions, moving from the low seventies to the high seventies and low eighties [28][30] Competitive Landscape - The company is aware of emerging competitors in the lipid-lowering market, including Novartis and other clinical-stage assets [35][36] - Esperion's unique positioning in primary prevention and the ability to use its drugs with or without statins is emphasized as a competitive advantage [43] International Opportunities - Esperion's partner Otsuka is expected to launch the drug in Japan by Q4 2023, with a significant market opportunity due to a large population unable to take statins [45][46] - The company anticipates profitability by January 2026, driven by international market expansion [47] Research and Development - Esperion is pursuing PSC as a new indication, leveraging ACLY biology to address liver disease [55][56] - The company aims to expedite the clinical timeline for PSC, with potential market entry before the early 2030s [68] Future Pipeline and Strategy - Esperion is considering a fixed-dose combination of statin and ezetimibe for the U.S. market, which would require only a bioequivalence study [70][71] - The company is exploring business development opportunities to leverage its existing infrastructure for marketing and selling other drugs [84][88] Intellectual Property - Esperion is currently involved in litigation with generic filers, with two settlements reached, and is planning for patent expiry in June 2031 [52][53] Conclusion - Esperion Therapeutics is positioned for growth with a strong commercial strategy, expanding sales force, and promising pipeline developments, particularly in the lipid-lowering and liver disease markets [51][88]

Esperion Therapeutics (ESPR) Q1 2025 Earnings Call May 06, 2025 08:00 AM ET Speaker0 Ladies and gentlemen, thank you for standing by and welcome. At this time, all participants are in a listen only mode. Following the presentation, there will be a question and answer session. Please be advised that today's conference call will be recorded. I would now like to hand the conference over to Alina Venezia, Director of Investor Relations for Esperion Therapeutics. Please go ahead. Speaker1 Thank you, operator. Go ...

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q4 2024 Earnings Conference Call March 4, 2025 8:00 AM ET Company Participants Alina Venezia - Director of Investor Relations Sheldon Koenig - President and Chief Executive Officer Ben Halladay - Chief Financial Officer Eric Warren - Chief Commercial Officer Conference Call Participants Dennis Ding - Jefferies Joseph Pantginis - H.C. Wainwright Thomas Shrader - BTIG Tanmay Patwardhan - JPMorgan Jason Zemansky - Bank of America Serge Belanger - Needham Paul Choi - Go ...